Realtive Bioavailability and pharmacokinetic profiling of a generic darifenacin formulation [Darisec extended release 15 mg] vs. the innovator [Enablex 15 mg] in healthy fed volunteers

Trial Profile

Realtive Bioavailability and pharmacokinetic profiling of a generic darifenacin formulation [Darisec extended release 15 mg] vs. the innovator [Enablex 15 mg] in healthy fed volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Darifenacin (Primary)
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 Jun 2016 Status changed from not yet recruiting to completed.
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top